Why the study?
Does dual antiplatelet therapy reduce stroke recurrence and composite vascular events in patients with acute non-cardioembolic ischaemic stroke or TIA compared to monotherapy?
Does dual antiplatelet therapy reduce stroke recurrence and composite vascular events in patients with acute non-cardioembolic ischaemic stroke or TIA compared to monotherapy?
In patients with acute non-cardioembolic stroke or TIA, dual antiplatelet therapy reduces stroke recurrence and composite vascular events but increases the risk of major bleeding compared to monotherapy.
No takes yet. Share an insight, caveat, or question.
Supports dual antiplatelet therapy after acute non-cardioembolic stroke or TIA; confirms reduced recurrence and vascular events versus monotherapy.
Yang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: